Caspofungin Study for Fungal Infections in Adults in Critical Care Settings
Status:
Terminated
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
Adults admitted to intensive care units are at risk for a variety of complications. One of
the most frequent complications is the development of new infections. Infections due to a
fungus called Candida are of particular concern. This study will test the possibility that
caspofungin, a new therapy for fungal infections, may reduce the rate of Candida infections
in subjects at risk.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)